ミネソタ州における慢性リンパ性白血病の臨床試験
ミネソタ州内の拠点で、慢性リンパ性白血病に関する29件の研究が参加者を募集しています。
ミネソタ州内の都市
公式研究テキスト（英語）
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Sanford Joe Lueken Cancer Center, Bemidji
- Essentia Health Saint Joseph's Medical Center, Brainerd
- Mercy Hospital, Coon Rapids
- 他9件
被験者募集中第3相
65歳以上 · 全性別 · 2026/10/02更新 · NCT07321652Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Riverwood Healthcare Center, Aitkin
- Mayo Clinic Health System in Albert Lea, Albert Lea
- Essentia Health - Baxter Clinic, Baxter
- 他48件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Mayo Clinic in Rochester, Rochester
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT03516617A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Research Site, Rochester
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/30更新 · NCT06542250Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Mercy Hospital, Coon Rapids
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- 他9件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT04269902A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Mayo Clinic Rochester, Rochester
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT06943872A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Mayo Clinic Rochester, Rochester
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05006716A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Mayo Clinic Rochester, Rochester
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07277231A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- University of Minnesota, Minneapolis
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT06846671A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Mayo Clinic Rochester, Rochester
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT06973187A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Regions Hospital ( Site 0042), Saint Louis Park
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/24更新 · NCT06136559A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Minnesota Oncology Hematology, P.A., Coon Rapids
被験者募集中第4相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07218341Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- University of Minnesota, Minneapolis
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/08更新 · NCT03666000A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Mayo Clinic Rochester, Rochester
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/08更新 · NCT05091424Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Mayo Clinic, Rochester
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/09/03更新 · NCT04588922Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Mayo Clinic, Clinical Trials Referral Office, Rochester
被験者募集中第1/2相
13歳〜90歳 · 全性別 · 2026/08/06更新 · NCT06533579Allo HSCT Using RIC and PTCy for Hematological Diseases
- Masonic Cancer Center at University of Minnesota, Minneapolis
被験者募集中第2相
75歳以下 · 全性別 · 2026/07/06更新 · NCT05805605Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
- Masonic Cancer Center at University of Minnesota, Minneapolis
被験者募集中第2相
60歳以下 · 全性別 · 2026/06/25更新 · NCT03314974A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
- Mayo Clinic, Rochester
被験者募集中第2相
18歳以上 · 全性別 · 2026/06/12更新 · NCT07271667CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
- Mayo Clinic in Rochester, Rochester
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/09更新 · NCT04892277The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients
- Mayo Clinic in Rochester, Rochester
被験者募集中健康なボランティア歓迎
18歳〜80歳 · 全性別 · 2026/04/09更新 · NCT05876923Hematopoiesis in MBL and CLL Versus Healthy Age-Matched Control Subjects
- Mayo Clinic in Rochester, Rochester
被験者募集中観察研究健康なボランティア歓迎
40歳以上 · 全性別 · 2026/03/31更新 · NCT06536452Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Mayo Clinic in Rochester, Rochester
被験者募集中第2相
18歳以上 · 全性別 · 2026/03/25更新 · NCT05388006A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Mayo Clinic- Minnesota, Rochester
被験者募集中第4相
18歳以上 · 全性別 · 2026/03/02更新 · NCT06876662A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Mayo Clinic- Minnesota, Rochester
被験者募集中第4相
18歳以上 · 全性別 · 2026/03/02更新 · NCT06876649Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
- Mayo Clinic in Rochester, Rochester
被験者募集中観察研究
全年齢 · 全性別 · 2026/02/27更新 · NCT06151730Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
- St. Lukes Hospital of Duluth /ID# 250021, Duluth
被験者募集中第2相
18歳以上 · 全性別 · 2026/02/09更新 · NCT04895436Family Study of Lymphoproliferative Disorders
- Mayo Clinic, Rochester
被験者募集中観察研究健康なボランティア歓迎
18歳〜100歳 · 全性別 · 2025/10/14更新 · NCT00626496Q702 for the Treatment of Patients With Hematologic Malignancies
- Mayo Clinic in Rochester, Rochester
被験者募集中第1相
18歳以上 · 全性別 · 2025/10/10更新 · NCT06712810ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。